Abstract. microRNAs (miRNAs) are short non-coding RNA sequences that play important roles in the regulation of gene expression. They have significant regulatory functions in basic cellular processes, including differentiation, proliferation and apoptosis. miRNAs are differentially expressed in tumors, compared with normal tissues. Importantly, miRNAs are also stable and abundantly present in body fluids and feces. The high reproducibility, sensitivity and specificity of miRNAs in body fluids and feces enable miRNAs to be used as potential molecular markers for cancer screening. An increasingly large number of research studies have reported the role of miRNAs in this field. In the present review, we focused mainly on the application of detecting miRNAs in stool, sputum, pleural effusion and urine, to detect colon, lung and urological cancers, highlighting the role of miRNAs in early diagnosis and prognosis.
IntroductionCancer is currently the most lethal human disease. Lung and colorectal cancers are the first and third most common types of cancers and the leading causes of cancer-related mortality worldwide (1). Bladder cancer, a urological cancer, is the second most common malignancy that involves the urinary system, and the clinical outcome is often poor once the tumor becomes invasive (2). Although much progress has been made in the prevention, early diagnosis and treatment of cancer, survival rates are still not optimistic, indicating that a more powerful method to detect cancer in the early stages is needed. Early detection of cancer has been reported to greatly improve both the survival rate and prognosis, suggesting that the key to oncotherapy may lie in early diagnosis (3-7). Thus, developing a method for the early detection of cancer is both important and necessary. Ideally, an early detection method would have high sensitivity, specificity and repeatability, and would be safe, affordable and acceptable to the patient as well.Traditional methods, such as colonoscopy (8), bronchoscopy (9) and cystoscopy (10), are used to detect colon cancer, non-small cell lung cancer (NSCLC) and bladder cancer, respectively. These methods have greatly benefited many individuals in the past and they are still used to diagnose cancer. However, their use has been hampered by their invasive nature, the manpower resources they require, their high cost and the discomfort they cause patients (11-13).Biological screening methods, including the fecal occult blood test (FOBT) for colon cancer; sputum cytology for NSCLC (14); and the bladder tumor antigen (BTA test), BTA stat test, nuclear matrix protein 22 (NMP22), and urinary cytology for bladder cancer, have also been applied in recent years. However, these methods each have a significant sensitivity (15,16) or specificity (13), but not both.As previously mentioned, these methods have drawbacks that prevent their wide application.